

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/065374 A1

(51) International Patent Classification⁷: **C07D 263/32**,
263/38, A61K 31/42

(21) International Application Number:
PCT/JP2004/000339

(22) International Filing Date: 16 January 2004 (16.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PR 2003900207 17 January 2003 (17.01.2003) AU
PR 2003901873 31 March 2003 (31.03.2003) AU

(71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi Osaka, 5418514, JP (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YAMAMOTO, Hirofumi [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi Osaka, 5418514 (JP). ISHIDA, Junya [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi Osaka, 5418514 (JP). TANABE, Daisuke [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi Osaka, 5418514 (JP). SATOH, Shigeki, [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi Osaka, 5418514 (JP). SAWADA, Yuki, [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi Osaka, 5418514 (JP). OHKAWA, Takehiko, [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi Osaka, 5418514 (JP). IMAMURA,

Kenichiro, [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi Osaka, 5418514 (JP). NAKAMURA, Katsuya, [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi Osaka, 5418514 (JP).

(74) Agents: KOTANI, Etsuji et al.; Nichimen Building 2nd Floor, 2-2, Nakanoshima 2-chome, Kita-ku, Osaka-shi Osaka, 5300005 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE



(57) Abstract: A compound of the formula (I): wherein R¹ is cycloalkyl, etc; R² is (lower)alkoxy, etc; R³ is (lower)alkylene, etc; R⁴ is (lower)alkylene, etc; R⁵ is hydroxy, etc; X is "O", "S", "SO", or "SO₂"; Y is "CH" or "N"; n is 0 or 1; or pharmaceutically acceptable salts thereof, which are useful as a medicament.